Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The GLP-1 medications can lower appetite for food and thirst for liquids
In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide lost an average of 22.5 percent of their body weight at 72 weeks (Jastreboff et al., NEJM , 2022), compared to roughly 15 percent with semaglutide 2.4 mg in the STEP 1 trial (Wilding et al., NEJM , 2021)
These questions matter because investments in GLP-1s only drive value if health improvements are sustained over time
In the last several months, weve seen first-of-their-kind products for these patients and the rebranding of existing formulas to target the drooping, dehydrating fallout of the drugs
The blog explores the Melanotan peptide, a research compound studied for its effects on skin pigmentation, UV protection and metabolism
While we didnt see phase 3 insulin sensitivity data, its clear that it profoundly reduces that just based on phase 2 data
